Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids

Trial Profile

A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dupilumab (Primary) ; Mometasone
  • Indications Nasal polyps; Rhinosinusitis
  • Focus Registrational; Therapeutic Use
  • Acronyms SINUS-24
  • Sponsors Regeneron Pharmaceuticals; Sanofi
  • Most Recent Events

    • 01 Dec 2023 Results of pooled analysis (n=688 from NCT02912468 and NCT02898454) assessing the relationship of sinus opacification, olfaction and dupilumab efficacy in patients with CRSwNP published in the Rhinology
    • 18 May 2022 Results of (SYNAPSE [mepolizumab], SINUS 24/52 [dupilumab], POLYP 1/2 [omalizumab]) assessing the feasibility of conducting an ITC to obtain unbiased estimates of the relative efficacy of biologics for treatment of uncontrolled chronic rhinosinusitis with nasal polyps, presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 25 Apr 2022 Data from three phase 3 studies (NCT01920893, NCT02912468 and NCT02898454) were used to validate chronic rhinosinusitis health-related quality-of-life outcome (HRQoL) measure through SNOT-22 domains were published in the Laryngoscope.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top